STOCK TITAN

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the BofA Securities Health Care Conference 2024. The presentation will take place on May 15, 2024, in Las Vegas, NV, featuring the company's President, CEO, and CFO. The webcast will be available on the company's website for replay. Xenon is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for neurological and psychiatric disorders, such as epilepsy and depression.

Positive
  • None.
Negative
  • None.

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.

Fireside Chat Presentation Details:
Date:Wednesday, May 15, 2024
Time:3:40 pm Pacific Time (6:40 pm Eastern Time)
Webcast:Register here
Presenters:Ian Mortimer, President and Chief Executive Officer
Sherry Aulin, Chief Financial Officer
  

A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Jodi Regts
Xenon Corporate Affairs
(604) 484-3353
media@xenon-pharma.com


FAQ

<p>When will Xenon Pharmaceuticals present at the BofA Securities Health Care Conference 2024?</p>

Xenon Pharmaceuticals will present at the BofA Securities Health Care Conference 2024 on May 15, 2024.

<p>What time will the presentation take place?</p>

The presentation will take place at 3:40 pm Pacific Time (6:40 pm Eastern Time) on May 15, 2024.

<p>Where will the conference be held?</p>

The BofA Securities Health Care Conference 2024 will take place in Las Vegas, NV.

<p>What is Xenon Pharmaceuticals focused on?</p>

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company.

<p>What areas of medical need does Xenon Pharmaceuticals address?</p>

Xenon Pharmaceuticals is addressing areas of high unmet medical need, including epilepsy and depression.

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

XENE Rankings

XENE Latest News

XENE Stock Data

2.87B
69.56M
0.38%
99.99%
3.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BURNABY

About XENE

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.